ATE347892T1 - Verwendung von nmda-antagonisten zur behandlung von schmerzen - Google Patents

Verwendung von nmda-antagonisten zur behandlung von schmerzen

Info

Publication number
ATE347892T1
ATE347892T1 AT94103212T AT94103212T ATE347892T1 AT E347892 T1 ATE347892 T1 AT E347892T1 AT 94103212 T AT94103212 T AT 94103212T AT 94103212 T AT94103212 T AT 94103212T AT E347892 T1 ATE347892 T1 AT E347892T1
Authority
AT
Austria
Prior art keywords
pain
methyl
treat pain
alleviating
antagonist
Prior art date
Application number
AT94103212T
Other languages
English (en)
Inventor
David J Mayer
Donald D Price
Jianren Mao
John W Lyle
Original Assignee
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26702161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE347892(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/027,177 external-priority patent/US5352683A/en
Application filed by Univ Virginia Commonwealth filed Critical Univ Virginia Commonwealth
Application granted granted Critical
Publication of ATE347892T1 publication Critical patent/ATE347892T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT94103212T 1993-03-05 1994-03-03 Verwendung von nmda-antagonisten zur behandlung von schmerzen ATE347892T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/027,177 US5352683A (en) 1993-03-05 1993-03-05 Method for the treatment of chronic pain
US9510793A 1993-07-21 1993-07-21

Publications (1)

Publication Number Publication Date
ATE347892T1 true ATE347892T1 (de) 2007-01-15

Family

ID=26702161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94103212T ATE347892T1 (de) 1993-03-05 1994-03-03 Verwendung von nmda-antagonisten zur behandlung von schmerzen

Country Status (7)

Country Link
US (1) US5502058A (de)
EP (1) EP0615749B1 (de)
JP (1) JP3018135B2 (de)
AT (1) ATE347892T1 (de)
CA (1) CA2115792C (de)
DE (1) DE69434891T2 (de)
ES (1) ES2281071T3 (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
WO1996009044A1 (en) * 1994-09-22 1996-03-28 Richard Alan Smith Compositions useful for the preparation of medicines for treating a variety of intractable disorders
US5840731A (en) * 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
CA2230690C (en) * 1995-08-30 2008-12-23 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
WO1997035584A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
ES2142703B1 (es) * 1996-07-09 2001-01-01 Univ Oviedo Farmacos inhibidores de calmodulina para su uso como analgesicos.
AU4078897A (en) * 1996-08-23 1998-03-06 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US5919826A (en) * 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
CA2272941A1 (en) * 1997-01-09 1998-07-16 Daniela Salvemini Attenuation of opioid tolerance by inhibiting inducible nitric oxide synthase pathways in the treatment of pain
EP1003494B1 (de) * 1997-01-22 2007-03-21 Cornell Research Foundation, Inc. (d)-METHADON, EIN NICHT-OPIOIDES SCHMERZMITTEL
WO1998050044A1 (en) * 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
PL193273B1 (pl) 1997-12-22 2007-01-31 Euro Celtique Sa Postać dawkowania doustnego
PL341309A1 (en) 1997-12-22 2001-04-09 Euro Celtique Method of preventing overdosage of opioidic preparations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
SE9801494D0 (sv) 1998-04-28 1998-04-28 Astra Pharma Prod Novel use
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
GB2339534A (en) * 1998-07-16 2000-02-02 Edko Trading Representation Epidural or intrathecal administration of NSAID's
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
US6329398B1 (en) * 1999-09-07 2001-12-11 Stephen M. Zappala Preemptive analgesic agent and methods of use
KR101476574B1 (ko) 1999-10-29 2014-12-24 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6207674B1 (en) 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
CN1423559A (zh) 2000-02-08 2003-06-11 欧罗赛铁克股份有限公司 包含阿片样激动剂和拮抗剂的控释组合物
EP1935421A1 (de) 2000-02-08 2008-06-25 Euro-Celtique S.A. Kontrolliert freigesetzte Zusammensetzungen mit einem Opioid-Agonisten und einem Opioid-Antagonisten
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
US7375136B2 (en) * 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
DK1395289T3 (da) * 2001-06-07 2011-03-28 Christine Dr Sang Behandling af neuropatisk smerte med en N-methyl-D-aspartat- (NMDA-)receptorantagonist
US7943173B2 (en) * 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003013433A2 (en) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
DE60232417D1 (de) 2001-08-06 2009-07-02 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
DK1321139T3 (da) * 2001-12-21 2007-01-02 Chiesi Farma Spa 2-indanylaminoderivater til behandling af kronisk, akut eller inflammatorisk smerte
CA2478523A1 (en) 2002-04-05 2003-10-16 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
TW200403066A (en) * 2002-04-30 2004-03-01 Novartis Ag New uses of substituted aminoalkanephosphonic acids
US20040010018A1 (en) * 2002-05-15 2004-01-15 Rueter Lynne E. Treatment of neuropathic pain
TWI326214B (en) 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US20080039461A1 (en) * 2002-09-05 2008-02-14 Protter Andrew A Treatment of pain by inhibition of p38 map kinase
EP2422772A3 (de) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestriermitteluntereinheit und zugehörige Zusammensetzungen und Verfahren
US20070298999A1 (en) * 2003-02-10 2007-12-27 Zaijie Wang Method for treating pain with a calmodulin inhibitor
US7256200B2 (en) * 2003-02-10 2007-08-14 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Method and composition for potentiating an oplate analgesic
US20100113563A1 (en) * 2004-01-30 2010-05-06 Zaijie Wang Method for Treating Pain with a Calmodulin Inhibitor
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050038062A1 (en) * 2003-04-14 2005-02-17 Burns Lindsay H. Methods and materials for the treatment of pain comprising opioid antagonists
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
EP1470818B1 (de) * 2003-04-25 2006-07-26 Neuro3D Verwendung von Piperazin- Phenothiazin- Derivaten zur Herstellung eines Arzneimittels mit neuroprotektiven und/oder neurotropischen Wirkungen auf das ZNS und/oder PNS
US20060205761A1 (en) * 2003-06-06 2006-09-14 Catherine Abbadie Ccr-2 antagonists for treatment of neuropathic pain
EP2298303A1 (de) 2003-09-25 2011-03-23 Euro-Celtique S.A. Pharmazeutische kombinationen von hydrocodon und naltrexon
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7454007B2 (en) * 2004-03-26 2008-11-18 Samsung Electronics Co., Ltd. Telecommunication switch using generic API to support multiple protocol-specific signal control functions
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
US20060004050A1 (en) * 2004-07-02 2006-01-05 Speicher Brian T Compositions and methods for the prevention or treatment of pain and other nervous system disorders
US20060019969A1 (en) * 2004-07-24 2006-01-26 Laboratorios Dr. Esteve S.A. Use of compounds active on the sigma receptor for the treatment of allodynia
EP1789028A2 (de) * 2004-08-24 2007-05-30 Neuromolecular Pharmaceuticals Inc Zusammensetzungen zur behandlung von nociceptiven schmerzen
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
WO2007017058A1 (en) * 2005-07-28 2007-02-15 Chiesi Farmaceutici S.P.A. Therapeutic combination comprising a nmda receptors blocker and a narcotic analgesic substance
KR20080097443A (ko) * 2006-02-03 2008-11-05 아바니르 파마슈티컬스 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
HUE032156T2 (en) * 2006-06-19 2017-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical preparations
EP2068840A2 (de) * 2006-07-21 2009-06-17 LAB International SRL Hydrophobes missbrauchssicheres ausgabesystem
CN101563085A (zh) * 2006-08-23 2009-10-21 威朗国际制药公司 作为钾通道调节剂的4-(n-氮杂环烷基)酰苯胺的衍生物
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
TW200815004A (en) * 2006-09-19 2008-04-01 Chi Mei Foundation Hospital Local anesthetic composition containing dextrorotatory morphinan derivative or pharmaceutically acceptable salts thereof
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
PT2117521E (pt) 2006-11-03 2012-09-10 Durect Corp Sistemas de administração transdérmica que compreendem bupivacaína
WO2008066900A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8420680B2 (en) * 2007-06-29 2013-04-16 Emory University NMDA receptor antagonists for neuroprotection
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
SI2317991T1 (sl) * 2008-07-07 2017-09-29 Euro-Celtique S.A. Uporaba opioidnih antagonistov za zdravljenje retencije urina
ES2706407T3 (es) 2009-03-10 2019-03-28 Euro Celtique Sa Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
PL2542241T3 (pl) * 2010-03-02 2016-12-30 Sposoby i kompozycje do leczenia lub zapobiegania objawom wahań hormonalnych
CA2991216C (en) 2010-12-22 2020-04-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
ES2581323T3 (es) 2010-12-23 2016-09-05 Purdue Pharma Lp Formas de dosificación oral sólida resistentes a alteraciones
BR112015017451B1 (pt) 2013-02-05 2023-01-10 Purdue Pharma L.P. Formulações farmacêuticas resistentes à violação
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
AU2014295042B2 (en) 2013-07-23 2017-03-30 Mundipharma Pty Limited A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US9682193B2 (en) * 2015-05-11 2017-06-20 Alcyone Lifesciences, Inc. Drug delivery systems and methods
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CA3045135A1 (en) 2016-12-21 2018-06-28 Alcyone Lifesciences, Inc. Drug delivery systems and methods
WO2023215277A1 (en) * 2022-05-02 2023-11-09 Undaunted Bio, Inc. Trimeprazine for use in treating trigeminal neuralgia and for reducing pain related thereto
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316888A (en) * 1980-04-15 1982-02-23 Nelson Research & Development Co. Method and composition of reducing pain
US4446140A (en) * 1981-12-10 1984-05-01 Nelson Research & Development Company Method and composition for treating mouth pain
CA1194799A (en) * 1981-12-10 1985-10-08 Eric L. Nelson Method and composition for reducing menstrual pain
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4806543A (en) * 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
IT1226800B (it) * 1988-09-16 1991-02-19 Prodotti Formenti Composizioni farmaceutiche orali contenenti sali di destrorfano.
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US5013540A (en) * 1989-11-30 1991-05-07 Board Of Regents, The University Of Texas System Using NMDA receptor antagonists to reduce damage due to laser treatment
GB9100028D0 (en) * 1991-01-02 1991-02-20 Ici Plc Compounds
US5164398A (en) * 1991-04-01 1992-11-17 Merck & Co., Inc. Ibuprofen-antitussive combinations
GB9208511D0 (en) 1991-05-09 1992-06-03 Ici Plc Compounds
WO1994000124A1 (en) 1992-06-22 1994-01-06 Eckard Weber Glycine receptor antagonists and the use thereof
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5352683A (en) * 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain

Also Published As

Publication number Publication date
ES2281071T3 (es) 2007-09-16
EP0615749B1 (de) 2006-12-13
JP3018135B2 (ja) 2000-03-13
EP0615749A3 (de) 1994-12-21
EP0615749A2 (de) 1994-09-21
DE69434891T2 (de) 2007-07-05
JPH072671A (ja) 1995-01-06
CA2115792C (en) 2005-11-01
CA2115792A1 (en) 1994-09-06
US5502058A (en) 1996-03-26
DE69434891D1 (de) 2007-01-25

Similar Documents

Publication Publication Date Title
ATE347892T1 (de) Verwendung von nmda-antagonisten zur behandlung von schmerzen
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
ES8505519A1 (es) Un procedimiento para la preparacion de 14-fluoromorfinanos utiles como analgesicos, narcoticos y-o agentes anorexicos.
ATE301994T1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda- antagonist
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
BG102668A (en) Application of ppar-alpha and prar-gamma antagonist for the treatment of syndrome x
IL128723A0 (en) Pharmaceutical compositions containing rar antagonists and rxr agonists
DE69123286D1 (de) Verwendung von 5-HT1A Rezeptoragonisten zur Hemmung der Magensäuresekretion
BG100692A (en) New heterocyclic compounds
MX9700030A (es) Administracion de pirenzipina, matilescopolamina y otros antagonistas del receptor mascurinico para el tratamiento de transtornos del metabolismo de lipidos.
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
DK0738269T3 (da) Piperidinderivater med PAF-antagonistaktivitet
ATE230993T1 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
DE69214588D1 (de) Methanoanthracene als Dopaminantagonisten
DE69214587D1 (de) Methanoanthracene als Dopaminantagonisten
ATE78162T1 (de) 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
ATE163850T1 (de) Pharmazeutische zusammensetzungen von 5ht1 agonistischen alkyl sulphonamidenfür rektale verabreichungen
DK0532177T3 (da) Methanoanthracener som dopaminantagonister

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties